Current Report · Items 8.01 · 8-K

Unicycive Therapeutics, Inc.

UNCYNASDAQEQUITYCurrent

Other Events

Filed Sep 28, 2026Accepted Sep 28, 2026, 4:31 PM EDTCIK 1766140Accession 0001213900-26-104076

Company context

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Current securities

UNCYNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Unicycive Therapeutics, Inc. · 8-K · Filed 2026-09-28

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol: UNCY
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: AsOf2026-09-03

Dimensions: Not supplied

Accession 000121390026104076 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events . On September 3, 2026, a securities class action lawsuit was filed in United States District Court for the Northern District of California against Unicycive Therapeutics, Inc. (the “Company”) and certain of its officers. This action alleges violations of the federal securities laws in connection with public statements by the Company relating to its new drug application for oxylanthanum carbonate phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The Company believes the claims are meritless and intends to vigorously defend the lawsuit. .

Get the free weekly BCS email.